Block Drug Salicylamide Feedback Meeting With FDA Requested
This article was originally published in The Tan Sheet
Executive Summary
Block Drug is asking for input from FDA on the adequacy of pharmacokinetic and clinical data to amend the internal analgesics tentative final monograph and reclassify salicylamide from a Category III to a Category I analgesic adjuvant with aspirin.
You may also be interested in...
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
A placebo-controlled, dose-response trial comparing acetaminophen to combinations of caffeine with aspirin and acetaminophen has been proposed by Bristol-Myers Squibb.
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
A placebo-controlled, dose-response trial comparing acetaminophen to combinations of caffeine with aspirin and acetaminophen has been proposed by Bristol-Myers Squibb.
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
A placebo-controlled, dose-response trial comparing acetaminophen to combinations of caffeine with aspirin and acetaminophen has been proposed by Bristol-Myers Squibb.